Allogeneic HSCT remains a major potentially curative treatment for patients with AML at high risk of relapse. However, the rapid development of targeted agents and novel non-intensive therapies has substantially changed the therapeutic landscape, raising questions regarding the optimal timing and indications for transp...
Simona Sica, F. Frioni, M. Breccia et al.· Mediterranean Journal of Hem...· 0 citations
Acute myeloid leukemia (AML) is a biologically heterogeneous hematologic malignancy in which recurrent cytogenetic and molecular abnormalities critically influence diagnostic classification, prognosis, therapeutic allocation, measurable residual disease (MRD) assessment, and relapse biology. Over the last decade, next-...
P. Chiusolo, R. Maggi, Angela Alessi et al.· Mediterranean Journal of Hem...· 0 citations
Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as an innovative treatment of haematologic malignancies; however, its use is frequently complicated by Cytokine Release Syndrome (CRS), an increasingly recognized driver of cancer therapy-related cardiovascular toxicity (CTR-CVT) able to provoke a wide spectrum...
M. Camilli, M. Ortenzi, L. Leo et al.· Journal of Cardiovascular Ph...· 0 citations
The prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma receiving commercial CAR‐T cells is evaluated, focusing on treatment‐related toxicities.
Eugenio Galli, D. Mannina, Alessandro Corrente et al.· European Journal of Haematol...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.